Connection
Navin Pinto to Treatment Outcome
This is a "connection" page, showing publications Navin Pinto has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.138 |
|
|
|
-
Pinto N, Künkele A, Albert CM, Taylor MR, Ullom HB, Vitanza NA, Wilson AL, Cole BL, Yeung CCS, Wright JH, Huang W, Wendler J, Seidel K, Brown C, Gustafson J, Rawlings-Rhea SD, Beebe A, Mgebroff S, Gardner RA, Jensen MC, Park JR. The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma. Clin Cancer Res. 2026 Sep 15; 32(18):4062-4074.
Score: 0.083
-
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17.
Score: 0.039
-
Desai AV, Applebaum MA, Karrison TG, Oppong A, Yuan C, Berg KR, MacQuarrie K, Sokol E, Hall AG, Pinto N, Wolfe I, Mody R, Shusterman S, Smith V, Foster JH, Nassin M, LaBelle JL, Bagatell R, Cohn SL. Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|